• Consensus Rating: Hold
  • Consensus Price Target: $311.25
  • Forecasted Upside: 24.48 %
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$250.05
▲ +5.65 (2.31%)

This chart shows the closing price for ABMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abiomed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABMD

Analyst Price Target is $311.25
▲ +24.48% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Abiomed in the last 3 months. The average price target is $311.25, with a high forecast of $355.00 and a low forecast of $235.00. The average price target represents a 24.48% upside from the last price of $250.05.

This chart shows the closing price for ABMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 3 contributing investment analysts is to hold stock in Abiomed. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
1/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
4/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
8/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2022Deutsche Bank AktiengesellschaftLower Target$410.00 ➝ $355.00Low
7/15/2022Morgan StanleyLower TargetUnderweight$275.00 ➝ $235.00Low
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$330.00High
2/4/2022Morgan StanleyLower TargetUnderweight$292.00 ➝ $275.00Low
2/4/2022SVB LeerinkLower TargetMarket Perform$345.00 ➝ $325.00Low
1/7/2022Morgan StanleyBoost TargetUnderweight$269.00 ➝ $292.00High
10/31/2021SVB LeerinkReiterated RatingHoldHigh
8/6/2021SVB LeerinkBoost TargetMarket Perform$335.00 ➝ $375.00Medium
8/6/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$360.00 ➝ $410.00Low
7/20/2021SVB LeerinkLower TargetMarket Perform$355.00 ➝ $335.00High
6/18/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$360.00High
6/6/2021SVB LeerinkReiterated RatingHoldLow
1/29/2021SVB LeerinkBoost TargetMarket Perform$320.00 ➝ $375.00Medium
1/29/2021Morgan StanleyBoost TargetUnderweight$238.00 ➝ $245.00Medium
1/28/2021Piper SandlerBoost TargetOverweight$350.00 ➝ $425.00High
12/21/2020SVB LeerinkBoost TargetPositive ➝ Market Perform$280.00 ➝ $320.00High
12/15/2020Morgan StanleyBoost TargetUnderweight$217.00 ➝ $238.00Medium
10/12/2020SVB LeerinkLower TargetMarket Perform$335.00 ➝ $280.00Medium
8/7/2020Morgan StanleyBoost TargetUnderweight$152.00 ➝ $217.00Medium
8/7/2020SVB LeerinkBoost TargetMarket Perform$280.00 ➝ $335.00Low
7/13/2020OTR GlobalUpgradePositiveHigh
5/28/2020SVB LeerinkBoost TargetMarket Perform$195.00 ➝ $225.00Low
5/27/2020BTIG ResearchDowngradeHoldHigh
5/1/2020Morgan StanleyBoost TargetUnderweight$149.00 ➝ $152.00Medium
4/27/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$220.00 ➝ $175.00High
3/27/2020Morgan StanleyLower TargetUnderweight$165.00 ➝ $149.00Low
3/23/2020Piper SandlerReiterated RatingBuy$240.00High
3/23/2020StephensLower TargetOverweight$240.00 ➝ $155.00High
2/11/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$198.00 ➝ $165.00High
2/6/2020BTIG ResearchInitiated CoverageHoldHigh
12/17/2019Morgan StanleyLower TargetEqual Weight$215.00 ➝ $198.00Low
11/1/2019SVB LeerinkBoost TargetOutperform$195.00 ➝ $240.00High
10/29/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
9/30/2019William BlairReiterated RatingBuyLow
8/2/2019William BlairReiterated RatingBuyLow
8/2/2019GuggenheimDowngradeBuy ➝ NeutralMedium
8/1/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$325.00 ➝ $215.00Medium
8/1/2019BTIG ResearchDowngradeBuy ➝ NeutralHigh
5/7/2019BTIG ResearchReiterated RatingBuyLow
5/3/2019SunTrust BanksReiterated RatingBuy$340.00Low
1/22/2019BTIG ResearchReiterated RatingBuy$400.00Low
1/2/2019Morgan StanleyLower TargetOverweight ➝ Overweight$496.00 ➝ $461.00High
11/7/2018Morgan StanleyUpgradeEqual ➝ Equal Weight$396.00 ➝ $496.00Medium
11/2/2018BTIG ResearchUpgradeNeutral ➝ Buy$450.00Low
10/11/2018Morgan StanleyBoost TargetEqual Weight$370.00 ➝ $396.00High
6/22/2018Piper Jaffray CompaniesBoost TargetOverweight$360.00 ➝ $480.00High
5/29/2018Jefferies Financial GroupBoost TargetBuy$460.00Medium
5/3/2018Piper Jaffray CompaniesBoost TargetOverweight$360.00High
5/1/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$259.00 ➝ $320.00Medium
4/4/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$332.00Medium
2/16/2018SunTrust BanksReiterated RatingBuy$370.00N/A
2/4/2018BTIG ResearchReiterated RatingHoldHigh
2/2/2018SVB LeerinkBoost TargetOutperform$300.00Low
2/2/2018Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$204.00 ➝ $259.00Low
2/2/2018GuggenheimReiterated RatingBuy$280.00Medium
2/1/2018Jefferies Financial GroupReiterated RatingBuy$300.00Medium
2/1/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$220.00 ➝ $300.00Medium
1/19/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$200.00 ➝ $265.00Low
1/12/2018Jefferies Financial GroupBoost TargetBuy$250.00Medium
1/4/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
12/21/2017Jefferies Financial GroupBoost TargetBuy$208.00 ➝ $220.00Medium
11/1/2017SunTrust BanksReiterated RatingBuy$195.00N/A
10/29/2017BTIG ResearchReiterated RatingHoldN/A
10/26/2017Piper Jaffray CompaniesBoost TargetOverweight$200.00N/A
10/16/2017BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/12/2017SVB LeerinkReiterated RatingOutperform$180.00 ➝ $200.00N/A
9/29/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$195.00High
9/29/2017Jefferies Financial GroupBoost TargetBuy$175.00 ➝ $208.00High
(Data available from 9/28/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/2/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/1/2022
  • 4 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
5/1/2022
  • 4 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/31/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/30/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/30/2022
  • 8 very positive mentions
  • 41 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2022
  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/28/2022

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Abiomed logo
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Read More

Today's Range

Now: $250.05
Low: $243.40
High: $251.58

50 Day Range

MA: $272.79
Low: $242.49
High: $301.46

52 Week Range

Now: $250.05
Low: $219.85
High: $379.30

Volume

263,933 shs

Average Volume

319,998 shs

Market Capitalization

$11.41 billion

P/E Ratio

52.75

Dividend Yield

N/A

Beta

1.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Abiomed?

The following Wall Street sell-side analysts have issued research reports on Abiomed in the last twelve months: Deutsche Bank Aktiengesellschaft, Morgan Stanley, StockNews.com, SVB Leerink LLC, and Wolfe Research.
View the latest analyst ratings for ABMD.

What is the current price target for Abiomed?

4 Wall Street analysts have set twelve-month price targets for Abiomed in the last year. Their average twelve-month price target is $311.25, suggesting a possible upside of 24.5%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting ABMD will reach $355.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $235.00 for Abiomed in the next year.
View the latest price targets for ABMD.

What is the current consensus analyst rating for Abiomed?

Abiomed currently has 1 sell rating and 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ABMD, but not buy more shares or sell existing shares.
View the latest ratings for ABMD.

What other companies compete with Abiomed?

How do I contact Abiomed's investor relations team?

Abiomed's physical mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider's listed phone number is (978) 646-1400 and its investor relations email address is [email protected] The official website for Abiomed is www.abiomed.com. Learn More about contacing Abiomed investor relations.